Duan Jinyi, Li Qinmei, Cheng Yan, Zhu Weifeng, Liu Hongning, Li Fei
Department of Gastroenterology & Hepatology Laboratory of Hepato-intestinal Diseases and Metabolism Frontiers Science Center for Disease-Related Molecular Network West China Hospital Sichuan University Chengdu China.
Deparment of Pharmacy, Academician Workstation Jiangxi University of Chinese Medicine Nanchang China.
MedComm (2020). 2024 Dec 16;5(12):e70017. doi: 10.1002/mco2.70017. eCollection 2024 Dec.
Increasing evidences indicate that the gut microbiota is involved in the development and therapy of gastrointestinal and hepatic disease. Imbalance of gut microbiota occurs in the early stages of diseases, and maintaining the balance of the gut microbiota provides a new strategy for the treatment of diseases. It has been reported that is associated with multiple diseases. As the next-generation probiotics, several studies have demonstrated its positive regulation on the gastrointestinal and hepatic disease, including inflammatory bowel disease, colorectal cancer, hepatic fibrosis, and fatty liver. The function of and its metabolites mainly affect host immune system, intestinal barrier function, and metabolic networks. Manipulation of with natural components lead to the protective effect on enterohepatic disease. In this review, the metabolic pathways regulated by are summarized to illustrate its active metabolites and their impact on host metabolism, the role and action mechanism in gastrointestinal and hepatic disease are discussed. More importantly, the natural components can be used to manipulate as treatment strategies, and the challenges and perspectives of in clinical applications are discussed.
越来越多的证据表明，肠道微生物群参与胃肠道和肝脏疾病的发生发展及治疗。肠道微生物群失衡在疾病早期就会出现，维持肠道微生物群的平衡为疾病治疗提供了新策略。据报道， 与多种疾病有关。作为下一代益生菌，多项研究已证明其对胃肠道和肝脏疾病具有正向调节作用，包括炎症性肠病、结直肠癌、肝纤维化和脂肪肝。 及其代谢产物的功能主要影响宿主免疫系统、肠道屏障功能和代谢网络。用天然成分调控 对肠肝疾病具有保护作用。在这篇综述中，总结了 调控的代谢途径，以阐明其活性代谢产物及其对宿主代谢的影响，讨论了其在胃肠道和肝脏疾病中的作用及作用机制。更重要的是，天然成分可用于调控 作为治疗策略，并讨论了 在临床应用中的挑战和前景。
